The effect of simultaneously blocking target epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2 on the growth of NPC cell.
- Author:
Shi-sheng LI
1
;
Xin ZHANG
;
Jing XU
;
Li XIE
;
Yuanzheng QIU
;
Xin SHU
;
Yongquan TIAN
Author Information
1. Department of Otorhinolaryngology, Affiliated Xiangya Hospital, Central South University, Changsha, 410008, China.
- Publication Type:Journal Article
- MeSH:
Apoptosis;
Celecoxib;
Cell Division;
Cyclooxygenase 2;
metabolism;
ErbB Receptors;
metabolism;
Erlotinib Hydrochloride;
Humans;
Pyrazoles;
administration & dosage;
pharmacology;
Quinazolines;
administration & dosage;
pharmacology;
Signal Transduction;
Sulfonamides;
administration & dosage;
pharmacology;
Tumor Cells, Cultured
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2009;23(18):817-823
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:This study was designed to prove simultaneously blocking both EGFR and COX-2-mediated pathways may be an efficient means of inhibiting cancer cell growth in NPC.
METHOD:A combination of tarceva (EGFR-selective tyrosine kinase inhibitors) with celecoxib (Cox-2 inhibitor) was studied on its effects on cell growth, cell cycle progression, apoptosis and protein expression in CNE-2 cell lines by cell growth assay, flow cytometric analysis assay and Western blotting.
RESULT:(1) The inhibition rate of cell growth was higher in the group treated with a combination of two agents than that the sum of rates of the two groups treated with only one agent (P < 0.05). (2) The combination of tarceva with celecoxib significantly induced G1 arrest (P < 0.05), but did not increase apoptosis rate (P > 0.05). (3) The group of combination showed less expressions of p-EGFR and COX-2 than any other group.
CONCLUSION:Simultaneously blocking EGFR and COX-2 mediated pathways would significantly inhibit the growth of CNE-2 cell line, increase G1 arrest and reduce the expression levels of p-EGFR and COX-2.
